MCID: WLM005
MIFTS: 20

Wilms Tumor 2 malady

Categories: Genetic diseases, Cancer diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Wilms Tumor 2

Aliases & Descriptions for Wilms Tumor 2:

Name: Wilms Tumor 2 54 29 13 69

Characteristics:

HPO:

32

Classifications:



External Ids:

OMIM 54 194071

Summaries for Wilms Tumor 2

MalaCards based summary : Wilms Tumor 2 is related to familial wilms tumor 2 and osteogenesis imperfecta, type v, and has symptoms including nephroblastoma An important gene associated with Wilms Tumor 2 is H19 (H19, Imprinted Maternally Expressed Transcript (Non-Protein Coding)). The drugs Doxorubicin and Daunorubicin have been mentioned in the context of this disorder.

Description from OMIM: 194071

Related Diseases for Wilms Tumor 2

Diseases in the Familial Wilms Tumor family:

Wilms Tumor 2 Hereditary Wilms' Tumor
Familial Wilms Tumor 2 Wilms Tumor 6

Diseases related to Wilms Tumor 2 via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 familial wilms tumor 2 12.0
2 osteogenesis imperfecta, type v 9.6 H19 KCNQ1DN WT2

Symptoms & Phenotypes for Wilms Tumor 2

Symptoms by clinical synopsis from OMIM:

194071

Clinical features from OMIM:

194071

Human phenotypes related to Wilms Tumor 2:

32
id Description HPO Frequency HPO Source Accession
1 nephroblastoma 32 HP:0002667

Drugs & Therapeutics for Wilms Tumor 2

Drugs for Wilms Tumor 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 258)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Daunorubicin Approved Phase 3,Phase 1,Phase 2 20830-81-3 30323
3
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
4
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
5
Idarubicin Approved Phase 2, Phase 3 58957-92-9 42890
6
Cytarabine Approved, Investigational Phase 2, Phase 3, Phase 1 147-94-4 6253
7
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
8
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
9
Azacitidine Approved, Investigational Phase 2, Phase 3,Phase 1 320-67-2 9444
10
Decitabine Approved, Investigational Phase 2, Phase 3 2353-33-5 451668
11
Dactinomycin Approved Phase 3,Phase 2 50-76-0 2019 457193
12
Cyclosporine Approved, Investigational, Vet_approved Phase 3 79217-60-0, 59865-13-3 5284373 6435893
13
Mycophenolic acid Approved Phase 3 24280-93-1 446541
14
Mycophenolate mofetil Approved, Investigational Phase 3 128794-94-5 5281078
15
Morphine Approved, Investigational Phase 3 57-27-2 5288826
16
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
17
Captopril Approved Phase 3 62571-86-2 44093
18
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
19
Ribavirin Approved Phase 3 36791-04-5 37542
20
Fluconazole Approved Phase 3 86386-73-4 3365
21
Histamine Approved, Investigational Phase 3,Phase 1,Phase 2 75614-87-8, 51-45-6 774
22
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
23
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
24
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
25
Palivizumab Approved, Investigational Phase 3 188039-54-5
26
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
27
Cyproheptadine Approved Phase 3 129-03-3 2913
28
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
29 Alkylating Agents Phase 3,Phase 2,Phase 1
30
protease inhibitors Phase 3,Phase 2
31 HIV Protease Inhibitors Phase 3,Phase 2
32 Cytochrome P-450 CYP3A Inhibitors Phase 3,Phase 2
33 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 2
34 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
35 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
36 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
37 Etoposide phosphate Phase 3,Phase 2,Phase 1
38 Anti-Infective Agents Phase 3,Phase 2,Phase 1
39 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
40 Liver Extracts Phase 3,Phase 2,Phase 1
41 Antimetabolites Phase 2, Phase 3, Phase 1
42 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
43 Antimetabolites, Antineoplastic Phase 2, Phase 3, Phase 1
44 Antimitotic Agents Phase 3,Phase 2,Phase 1
45 Antirheumatic Agents Phase 3,Phase 2,Phase 1
46 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
47 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
48 Antiviral Agents Phase 3,Phase 2,Phase 1
49 Acyclovir Phase 3
50 valacyclovir Phase 3

Interventional clinical trials:

(show top 50) (show all 158)
id Name Status NCT ID Phase
1 Collaborative Wilms Tumour Africa Project Recruiting NCT01991652 Phase 4
2 Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Unknown status NCT01809392 Phase 2, Phase 3
3 WT1 for the Detection of Minimal Residual Disease Completed NCT00179829 Phase 2, Phase 3
4 Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML) Completed NCT00909168 Phase 2, Phase 3
5 Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer Completed NCT00369564 Phase 3
6 Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer Completed NCT00002611 Phase 3
7 Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk Completed NCT00860639 Phase 3
8 A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old Completed NCT00927498 Phase 3
9 HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk Completed NCT02461121 Phase 3
10 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3
11 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
12 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3
13 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3
14 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
15 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3
16 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3
17 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
18 Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia Unknown status NCT01513109 Phase 1, Phase 2
19 WT1 Peptid Vaccination in Carcinomas Unknown status NCT00153608 Phase 2
20 WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML) Unknown status NCT00153582 Phase 2
21 Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney Unknown status NCT00025103 Phase 2
22 Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma Unknown status NCT00965224 Phase 2
23 Dendritic Cell Vaccination for Patients With Solid Tumors Unknown status NCT01291420 Phase 1, Phase 2
24 Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Unknown status NCT00179816 Phase 1, Phase 2
25 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
26 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2
27 A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms' Tumor Completed NCT00001509 Phase 2
28 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Completed NCT01502410 Phase 2
29 Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers Completed NCT00488592 Phase 2
30 Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood Completed NCT00923910 Phase 1, Phase 2
31 Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy Completed NCT01819558 Phase 1, Phase 2
32 A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor Completed NCT00187031 Phase 2
33 Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy Completed NCT00433745 Phase 2
34 Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation Completed NCT00052520 Phase 1, Phase 2
35 Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer Completed NCT00002466 Phase 2
36 Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors Completed NCT00335556 Phase 2
37 To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer Completed NCT01222780 Phase 1, Phase 2
38 Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies Completed NCT00038207 Phase 2
39 Safety and Efficacy Study of T-Guard to Treat Steroid-resistant Acute GVHD Completed NCT02027805 Phase 1, Phase 2
40 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
41 Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Completed NCT00024258 Phase 2
42 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2
43 Pharmacokinetic Study of Doxorubicin in Children With Cancer Completed NCT01095926 Phase 2
44 Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers Completed NCT00141765 Phase 2
45 Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant Completed NCT00309907 Phase 2
46 Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy Completed NCT00066599 Phase 2
47 Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer Completed NCT00003408 Phase 2
48 Ixabepilone in Treating Young Patients With Refractory Solid Tumors Completed NCT00331643 Phase 2
49 Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors Completed NCT00005952 Phase 1, Phase 2
50 Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors Completed NCT00365768 Phase 2

Search NIH Clinical Center for Wilms Tumor 2

Genetic Tests for Wilms Tumor 2

Genetic tests related to Wilms Tumor 2:

id Genetic test Affiliating Genes
1 Wilms Tumor 2 29

Anatomical Context for Wilms Tumor 2

Publications for Wilms Tumor 2

Variations for Wilms Tumor 2

ClinVar genetic disease variations for Wilms Tumor 2:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 H19 H19, 5.3-KB DEL deletion Pathogenic
2 H19 H19, 1.43-KB TRIPLICATION undetermined variant Pathogenic
3 H19; H19-ICR; ICR1; MRPL23 NR_002196.1(H19): n.-7080_-1781del deletion Pathogenic GRCh38 Chromosome 11, 1999616: 2004919
4 H19; H19-ICR; ICR1; MRPL23 GRCh38/hg38 11p15.5(chr11: 2000799-2001783)x3 copy number gain Pathogenic GRCh37 Chromosome 11, 2022018: 2023452

Expression for Wilms Tumor 2

Search GEO for disease gene expression data for Wilms Tumor 2.

Pathways for Wilms Tumor 2

GO Terms for Wilms Tumor 2

Sources for Wilms Tumor 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....